NSPR_OUT_1 [2025-04-29 10:05:18 -0400] 6271 Bytes | 1701 tokens | Cum: 1701 tkns (21.26% of 8k)
==========================================================================

You're the expert here today. I just pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and InspireMD (NSPR) hit my radar screen, up to $2.68 from a prev close of $2.32 Do you think its got more juice or is it lacking potential? It's 10:05 AM on Tue Apr 29, 2025 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: InspireMD (NSPR)
IPO: 1997-08-22 (27 Years Ago)
Market Cap: $79,651,900
Shares Outstanding: 30,640,000
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange: XNAS
Description: InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Here’s a list of headlines for InspireMD:

Apr-25-25 09:00AM - InspireMD to Announce First Quarter 2025 Financial Results
Apr-08-25 09:00AM - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar-26-25 09:00AM - InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
Mar-13-25 03:04AM - InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ...
Mar-12-25 07:00AM - InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results
Feb-26-25 08:00AM - InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results
Feb-25-25 08:00AM - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb-13-25 07:00AM - InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime 80 cm Carotid Stent System for Use in TCAR procedures
Feb-04-25 07:00AM - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan-21-25 07:00AM - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec-12-24 07:00AM - InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025
Dec-09-24 07:00AM - InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
Nov-25-24 04:05PM - InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
Nov-13-24 02:09AM - InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...
Nov-12-24 07:00AM - InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov-11-24 07:25AM - What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings
Nov-08-24 05:30PM - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov-04-24 08:00AM - InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th
Oct-15-24 07:00AM - InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
Oct-08-24 07:28AM - InspireMD Advances with FDA Study Approval and Global Goals
Oct-07-24 07:00AM - InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
Sep-16-24 07:00AM - InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard Prime Carotid Stent System

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-25T13:00:00Z - InspireMD to Announce First Quarter 2025 Financial Results
B2 - 2025-02-13T12:00:00Z - InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
B3 - 2024-10-15T11:00:00Z - InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
B4 - 2024-09-16T11:00:00Z - InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
B5 - 2024-05-28T12:53:00Z - InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024  
B6 - 2024-05-06T21:45:07Z - Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for InspireMD (NSPR).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

NSPR_OUT_3 [2025-04-29 10:05:19 -0400] 704 Bytes | 205 tokens | Cum: 1908 tkns (23.85% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**InspireMD to Announce First Quarter 2025 Financial Results**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/25/3068311/0/en/InspireMD-to-Announce-First-Quarter-2025-Financial-Results.htmlInspireMD, Inc. (Nasdaq: NSPR) announced that it will release its Q1 2025 financial results on May 9, 2025, and host a conference call to discuss the results and recent highlights.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NSPR_OUT_5 [2025-04-29 10:05:19 -0400] 898 Bytes | 284 tokens | Cum: 2194 tkns (27.43% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-25T13:29:35Z - InspireMD to Announce First Quarter 2025 Financial Results | Taiwan News | Apr. 25, 2025 21:00...
A2 - 2025-04-25T13:05:22Z - InspireMD to Announce First Quarter 2025 Financial Results...
A3 - 2025-04-20T06:39:20Z - InspireMD (NYSE:NSPR) Now Covered by StockNews.com...
A4 - 2025-04-13T05:36:08Z - StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)...
A5 - 2025-04-08T13:24:43Z - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Taiwan News | Apr. 8, 2...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

NSPR_OUT_7 [2025-04-29 10:05:20 -0400] 1183 Bytes | 339 tokens | Cum: 2535 tkns (31.69% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**InspireMD to Announce First Quarter 2025 Financial Results | Taiwan News | Apr. 25, 2025 21:00**Date: 2025-04-25Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6095139MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be acc

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NSPR_OUT_9 [2025-04-29 10:05:21 -0400] 1182 Bytes | 288 tokens | Cum: 2825 tkns (35.31% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): essed by visiting InspireMD's website or by registering below. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on InspireMD's website.

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713642&tp_key=1c3c464032

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD's common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

Investor Contact:

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

[email protected]

Webb Campbell

Gilmartin Group LLC

[email protected]

[email protect

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NSPR_OUT_11 [2025-04-29 10:05:22 -0400] 286 Bytes | 85 tokens | Cum: 2912 tkns (36.40% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): ed]

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NSPR_OUT_13 [2025-04-29 10:05:24 -0400] 1099 Bytes | 278 tokens | Cum: 3192 tkns (39.90% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-12 8-K Item 2.02 Results of Oper and Fin Cond.

On March 12, 2025, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the fourth quarter and year ended December 31, 2024. A copy of this press release is attac...

S2 - 2025-03-12 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying CONS financial statements and re...

S3 - 2024-12-12 8-K Item 7.01. Regulation FD Disclosure.

On December 12, 2024, the Company issued a press release titled InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Curr Repo...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NSPR_OUT_15 [2025-04-29 10:05:24 -0400] 1181 Bytes | 283 tokens | Cum: 3477 tkns (43.46% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 2.02 Results of Operations and Financial Condition.

On March 12, 2025, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the fourth quarter and year ended December 31, 2024. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set fort

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NSPR_OUT_17 [2025-04-29 10:05:25 -0400] 325 Bytes | 92 tokens | Cum: 3571 tkns (44.64% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): h by specific reference in such filing....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NSPR_OUT_19 [2025-04-29 10:05:37 -0400] 5888 Bytes | 1578 tokens | Cum: 5151 tkns (64.39% of 8k)
==========================================================================

This is our set of metrics for InspireMD.
Please analyze the numbers.

+--------------------+----------------------+-------------------------+-----------------------+
| Volume: 36,034 | Perf Month: -6.30% | Option/Short: Yes / Yes | Sales Y/Y TTM: 12.96% |
+--------------------+----------------------+-------------------------+-----------------------+
| Avg Volume: 58.13K | Perf Quarter: -0.78% | Short Float: 0.98% | ROE: -84.68% |
+--------------------+----------------------+-------------------------+-----------------------+
| Rel Volume: 6.28 | Index: - | Short Ratio: 3.30 | ROI: -84.49% |
+--------------------+----------------------+-------------------------+-----------------------+
| RSI (14): 45.62 | Market Cap: 77.50M | Short Interest: 0.19M | Sales Surprise: 7.29% |
+--------------------+----------------------+-------------------------+-----------------------+
| ATR (14): 0.16 | Shs Outstand: 26.61M | Beta: 0.64 | EPS Surprise: 2.56% |
+--------------------+----------------------+-------------------------+-----------------------+
| SMA20: -1.91% | Shs Float: 19.53M | Sales Q/Q: 10.68% | P/E: - |
+--------------------+----------------------+-------------------------+-----------------------+
| SMA50: -9.41% | Inst Own: 35.75% | Sales past 5Y: 19.13% | Earnings: May 09 BMO |
+--------------------+----------------------+-------------------------+-----------------------+
| SMA200: -7.79% | Insider Own: 36.24% | Employees: 86 | |
+--------------------+----------------------+-------------------------+-----------------------+
| Perf Week: -0.78% | Insider Trans: 0.00% | Debt/Eq: 0.06 | |
+--------------------+----------------------+-------------------------+-----------------------+

The next section covers any insider trading by InspireMD officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 7009000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -32005000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.68
Average Volume: 39290.33
30-Day High: 2.69
30-Day Low: 2.32

[Detailed Financials: TTM 2024]
- Total Assets: $46,807,000.00
- Total Liabilities: $10,721,000.00
- Total Equity: $36,086,000.00
- Current Assets: $40,521,000.00
- Current Liabilities: $7,678,000.00

[Income Statement: TTM 2024]
- Revenue: $7,009,000.00
- Net Income: $-32,005,000.00
- Gross Profit: $1,506,000.00
- Operating Income: $-33,503,000.00
- Earnings Per Share (EPS): -0.76

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $9,225,000.00

[Detailed Financials: FY 2024]
- Total Assets: $46,807,000.00
- Total Liabilities: $10,721,000.00
- Total Equity: $36,086,000.00
- Current Assets: $40,521,000.00
- Current Liabilities: $7,678,000.00

[Income Statement: FY 2024]
- Revenue: $7,009,000.00
- Net Income: $-32,005,000.00
- Gross Profit: $1,506,000.00
- Operating Income: $-33,503,000.00
- Earnings Per Share (EPS): -0.76

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $9,225,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of InspireMD (NSPR).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about InspireMD.

2) MARKET_SCORE[]
This conversation was initiated because NSPR is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for NSPR.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, NSPR could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect NSPR to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of InspireMD.

11) ETHICAL_RATING[]
Rate InspireMD’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of InspireMD.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

NSPR_IN_21 [2025-04-29 10:05:38 -0400] 126 Bytes | 29 tokens | Cum: 5369 tkns (67.11% of 8k)
==========================================================================

====================================
[2025-04-29 10:05:38] # Analysis Completed
Elapsed Time: 20.65 seconds